Signos Raises $13M Series A To Give You Real-Time Weight-Loss Advice Based On Your Blood Glucose Levels
Signos Raises $13M Series A To Give You Real-Time Weight-Loss Advice Based On Your Blood Glucose Levels
11/10/21, 1:01 PM
Location
the united statesMoney raised
$13 million
Round Type
series a
In a world where we count every step and measure every heartbeat, hopping on the scale once per week to keep half an eye on what your body is doing just won’t do. Even if you stand around on the glass oracle of mass a few times per day, the truth is that your body weight is a trailing indicator — it shows what has already happened, rather than what’s about to. One leading indicator is your blood sugar level — and weight-loss startup Signos is betting that you’re curious enough about the difference between our respective metabolisms to sign up for real-time glucose monitoring and alerts to keep you in shape. It turns out that GV believes that, too, to the tune of leading the company’s $13 million Series A round.
Company Info
Location
the united states, washington, united states
Additional Info
The company today revealed that it has raised a total of $17 million in funding, including a $4 million seed funding led by Courtside Ventures, 1984 Ventures and Tau Ventures back in January. Elite athletes or conscientious dieters often take an extraordinary amount of trial and error to come to the same conclusion we are able to deliver in a fraction of the time.”The Signos platform will help develop personalized answers to basic questions like what to eat, when to eat and what exercises help encourage weight loss. The right time to take action, the company claims, is as the glucose level is on the upswing.“Having this immediate continuous feedback loop over a longer period of time yields better results for our members to achieve the sort of health outcomes that they’re trying to achieve,” claims Fouladgar-Mercer. The company says it has more than 100,000 potential customers waiting for the product to become available, and it says that the new funding round means that the product will be available across the U.S. at some point in 2022. Once calibrated, Signos uses that data to provide personalized nutrition suggestions, including which foods are best for each user, when to eat and when to exercise to bring glucose levels back within their optimal weight loss range.